Please login to the form below

Not currently logged in
Email:
Password:

Pharma and BRIC

This page shows the latest Pharma and BRIC news and features for those working in and with pharma, biotech and healthcare.

Building and delivering market access capabilities in emerging markets

Building and delivering market access capabilities in emerging markets

Within these markets the BRIC countries (Brazil, Russia, India and China) are the dominant players. ... Positioning for growth in BRIC countries is an important strategy for pharma companies.

Latest news

  • All eyes on pharma in Brazil All eyes on pharma in Brazil

    Partnering with big pharma minimises operational risks but, in addition to reduced control over sales, marketing and other processes, royalties rather than sales will diminish sales profitability. ... This article was originally published in the

  • Brazil's healthcare conundrum Brazil's healthcare conundrum

    There is no doubting that Brazil is a major emerging market and one that many big pharma organisations will be keeping a close eye on in the future. ... This article was orginially published in the PME supplement Pharma and BRIC.

  • BRIC 'not delivering' on promises of high growth BRIC 'not delivering' on promises of high growth

    This is according to a new report by analysts Frost &Sullivan, which says that pharma firms expanding into emerging markets like Brazil, Russia, India and China ( BRIC) are realising “ there are ... For more on the impact of the BRIC nations, read

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • The MISTs of time - new emerging markets The MISTs of time - new emerging markets

    Beyond BRIC. It is increasingly clear that the global pharma sector, like many developed industries, is looking outside its traditional and mature markets for sustainable long-term growth. ... This article was originally published in the

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    For as long as pharma and biotech companies have contemplated doing business in BRIC, there have been questions about intellectual property (IP) risk. ... This article was originally published in the PME supplement Pharma and BRIC.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    At present, pharma is steadily putting the building bricks in place, but as the BRIC economies mature and local healthcare systems become embedded, the growth opportunities in these key disease areas ... This article was originally published in the

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    There are increasing examples of pharma companies collaborating with governmental and quasi-governmental institutions in BRIC countries. ... This article was originally published in the PME supplement Pharma and BRIC.

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Building BRICs: pharma's key emerging markets are becoming giants. The BRIC nations – Brazil, Russia, India and China – for so long the leading lights of the emerging markets movement, may soon ... This article was originally published in the

More from intelligence
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics